TRIple Negative Breast Cancer Markers In Liquid Biopsies Using Artificial Intelligence
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Triple negative breast cancer (TNBC) is the most aggressive of breast cancers and it is usually treated with chemotherapy even before surgery. In many cases, the chemotherapy completely "melts" the tumor and these patients do well. When the tumor is not eliminated by the chemotherapy, the patient receive more chemotherapy after surgery to decrease the chances of it coming back. Yet many of these patients don't need that extra chemotherapy and will do well in any case. One of the most exciting recent developments in cancer is the use of "liquid biopsies". It turns out that the tumor's DNA, RNA and proteins can be detected in small vesicles found in the patient's blood. Thanks to advances in Artificial Intelligence, there is now informatics tools to integrate many types of molecular information. Our industrial partner, MIMs, will apply novel informatics tools to generate a test using all the molecular information obtained from blood vesicles and tissue that will be able to find out early if tumor has spread outside of the breast, and how much tumor is left after surgery. The goal is hope to develop a multi-dimensional test for TNBC patients that can be used to decide how much treatment they need and if treatment given after surgery is working.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Nowotwór potrójnie ujemny (brak receptorów estrogenowych, progesteronowych i HER2)
- •Ukończenie minimum 8 tygodni chemioterapii przed operacją
- •Pozostałości nowotworu widoczne w badaniach przed operacją lub znalezione podczas operacji
- •Możliwość regularnych wizyt w przychodni przez 6 miesięcy po operacji
- •Chęć oddawania próbek krwi do badań
- •Gotowość do uczestnictwa w harmonogramie wizyt i badań przewidzianych w badaniu
✗ Disqualifies
- •Przerzuty nowotworu do innych części ciała
- •Wznowa raka piersi w przeszłości
- •Brak chemioterapii przed operacją lub mniej niż 8 tygodni chemioterapii
- •Radioterapia przeprowadzona przed operacją
- •Brak zdolności do zrozumienia i podpisania dokumentu zgody
- •Zakażenie HIV lub wirusem zapalenia wątroby
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- November 28, 2025
- Sex
- No restrictions
Therapies / drugs in trial
Locations (3)
St. Joseph's Health Care London
London, Canada
The Ottawa Hospital Cancer Center
Ottawa, Canada
Jewish General Hospital
Montreal, Canada
Trial contact
Adriana Aguilar, PhD
Josiane Lafleur, MSc
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.